ACM
CLGN icon

ACT Capital Management’s CollPlant Biotechnologies CLGN Stock Holding History

ACT Capital Management’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,500
Closed -$127K – 100
2021
Q3 		$127K Hold
7,500
– – 0.07% 88
2021
Q2 		$160K Buy
+7,500
New +$120K 0.08% 88

Other funds holding CLGN

IMOV
Investment Management of Virginia Richmond, Virginia $526M AUM 3.23% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
BFEC
Benjamin F. Edwards & Company St. Louis, Missouri $5.69B AUM 15.37% 1-Year Est. Return
Zurich Cantonal Bank
Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return
WC
Weil Company San Diego, California $445M AUM 14.95% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
KWM
Kingsview Wealth Management Grants Pass, Oregon $7.33B AUM 16.07% 1-Year Est. Return

ACT Capital Management's CLGN Position: Q4 2021 in Review

ACT Capital Management sold out of CollPlant Biotechnologies (CLGN) in Q4 2021, closing a stake of 7,500 shares — an estimated $127K sold.

ACT Capital Management first reported a position in CLGN in Q2 2021 and held it in 2 quarters. The position peaked at $160K in Q2 2021. 21 funds tracked by Wall St. Rank hold CLGN as of Q4 2021.

  • ACT Capital Management reported no remaining CollPlant Biotechnologies position as of Q4 2021 after selling out during the quarter.
  • ACT Capital Management sold 7,500 CollPlant Biotechnologies shares in Q4 2021, an estimated $127K.
  • ACT Capital Management first reported a position in CollPlant Biotechnologies in Q2 2021 and held it in 2 quarters.
  • ACT Capital Management's CollPlant Biotechnologies position peaked at $160K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q4 2021.

Based on ACT Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.